{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/RLMD/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T17:54:43.558Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3828,"canonical_name":"RELMADA THERAPEUTICS, INC.","cik":"0001553643","uei":null,"lei":null,"duns":null,"ticker":"RLMD"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":17},"count":17,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — RELMADA THERAPEUTICS, INC. — 2026-09-11","url_slug":"/sec/cik-0001553643/4/0001213900-26-098969","accession_number":"0001213900-26-098969","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — RELMADA THERAPEUTICS, INC. — 2026-09-11","url_slug":"/sec/cik-0001553643/4/0001213900-26-098970","accession_number":"0001213900-26-098970","importance":30},{"ts":"2026-09-10","kind":"sec.insider.p","reporter":"TRAVERSA SERGIO","title":"Chief Executive Officer","shares":100000,"price_per_share":4.1,"usd_value":410000,"security_title":"Common Stock","importance":50.41},{"ts":"2026-09-10","kind":"sec.insider.p","reporter":"Shenouda Maged","title":"Chief Financial Officer","shares":79800,"price_per_share":4.25,"usd_value":339150,"security_title":"Common Stock","importance":50.33915},{"ts":"2026-09-09","kind":"sec.insider.p","reporter":"Shenouda Maged","title":"Chief Financial Officer","shares":120200,"price_per_share":4.2,"usd_value":504840,"security_title":"Common Stock","importance":50.50484},{"ts":"2026-09-09","kind":"sec.insider.p","reporter":"TRAVERSA SERGIO","title":"Chief Executive Officer","shares":100000,"price_per_share":4.18,"usd_value":418000,"security_title":"Common Stock","importance":50.418},{"ts":"2026-09-08","kind":"sec.filing","form_type":"8-K","title":"8-K — RELMADA THERAPEUTICS, INC. — 2026-09-08","url_slug":"/sec/cik-0001553643/8-k/0001213900-26-097851","accession_number":"0001213900-26-097851","importance":35},{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — RELMADA THERAPEUTICS, INC. — 2026-08-14","url_slug":"/sec/cik-0001553643/schedule-13g-a/0002050709-26-000025","accession_number":"0002050709-26-000025","importance":30},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — RELMADA THERAPEUTICS, INC. — 2026-08-06","url_slug":"/sec/cik-0001553643/10-q/0001213900-26-086151","accession_number":"0001213900-26-086151","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — RELMADA THERAPEUTICS, INC. — 2026-08-06","url_slug":"/sec/cik-0001553643/8-k/0001213900-26-086190","accession_number":"0001213900-26-086190","importance":35},{"ts":"2026-07-29","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — RELMADA THERAPEUTICS, INC. — 2026-07-29","url_slug":"/sec/cik-0001553643/schedule-13g/0002012383-26-002872","accession_number":"0002012383-26-002872","importance":55},{"ts":"2026-07-28","kind":"sec.filing","form_type":"8-K","title":"8-K — RELMADA THERAPEUTICS, INC. — 2026-07-28","url_slug":"/sec/cik-0001553643/8-k/0001213900-26-082007","accession_number":"0001213900-26-082007","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"S-8","title":"S-8 — RELMADA THERAPEUTICS, INC. — 2026-06-18","url_slug":"/sec/cik-0001553643/s-8/0001213900-26-070097","accession_number":"0001213900-26-070097","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — RELMADA THERAPEUTICS, INC. — 2026-06-09","url_slug":"/sec/cik-0001553643/schedule-13g/0001738048-26-000066","accession_number":"0001738048-26-000066","importance":55},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-3ASR","title":"S-3ASR — RELMADA THERAPEUTICS, INC. — 2026-05-13","url_slug":"/sec/cik-0001553643/s-3asr/0001213900-26-055901","accession_number":"0001213900-26-055901","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — RELMADA THERAPEUTICS, INC. — 2026-05-12","url_slug":"/sec/cik-0001553643/10-q/0001213900-26-055059","accession_number":"0001213900-26-055059","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — RELMADA THERAPEUTICS, INC. — 2026-05-12","url_slug":"/sec/cik-0001553643/8-k/0001213900-26-055164","accession_number":"0001213900-26-055164","importance":35}]}